Back to results
US 2007/0190068 A1Published application
uPAR-binding molecule-drug conjugates and uses thereof
OwnerRichard Hart, Shafaat Rabbaniinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerRichard Hart, Shafaat Rabbaniinventors
Estimating the term…
The present invention relates to the use of uPAR-binding molecule-drug conjugates capable of specifically binding a urokinase plasminogen activator receptor (uPAR) as therapeutic and diagnostic reagents for the treatment and monitoring of metastases. The present invention provides methods of treatment of metastases, comprising administering to a subject a uPAR-binding molecule-chemotherapeutic conjugate that is capable of binding to and internalizing into uPAR-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention further provides methods and compositions relating to combination therapy for cancer involving or mediated by uPAR-expressing cells using uPAR-binding molecule-drug conjugates of the invention.
A conjugate molecule comprising a first portion which comprises a uPAR-binding molecule and a second portion which comprises a drug, wherein the uPAR-binding molecule specifically binds to an epitope recognized by anti-human uPAR monoclonal antibody 3936, wherein said drug is a chemotherapeutic agent, and wherein the conjugate is capable of being internalized into a uPAR-expressing cell.
A method of treating, ameliorating or preventing metastasis involving uPAR-expressing cells in a subject having cancer, the method comprising administering to said subject an effective amount of a conjugate molecule comprising a first portion which comprises a uPAR-binding molecule and a second portion which comprises a chemotherapeutic agent, wherein the uPAR-binding molecule specifically binds to an epitope recognized by anti-human uPAR monoclonal antibody 3936 and wherein the conjugate molecule is internalized by a uPAR-expressing cell.
-39. (canceled)
A kit comprising a conjugate molecule in a container, said conjugate molecule comprises a uPAR-binding molecule which immunospecifically binds to an epitope recognized by anti-human uPAR monoclonal antibody 3936, said uPAR-binding molecule is conjugated to a chemotherapeutic agent.
Dependencies are inferred from the claim text.